Ichthyoses

Clinical, Biochemical, Pathogenic and Diagnostic Assessment

Elias, P.M. (San Francisco, CA)
Williams, M.L. (San Francisco, CA)
Crumrine, D. (San Francisco, CA)
Schmuth, M. (Innsbruck)

Chapter 3

Inherited Disorders of Accelerated Desquamation

Elias P.M. · Williams M.L. · Crumrine D. · Schmuth M.

Related Articles for ""
Elias PM, Williams ML, Crumrine D, Schmuth M (eds): Curr Probl Dermatol. Basel, Karger, 2010, vol 39, pp 89–97
https://doi.org/10.1159/000321085

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Published online: September 14, 2010
Cover Date: 2010

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9394-6 (Print)
eISBN: 978-3-8055-9395-3 (Online)


First-Page Preview
Abstract of Chapter 3


Related Articles:

References

  1. Traupe H: Ichthyosis: A Guide to Clinical Diagnosis, Genetic Counseling, and Therapy. New York, Springer, 1989;253
  2. Judge MR, Morgan G, Harper JI: A clinical and immunological study of Netherton's syndrome. Br J Dermatol 1994;131:615-621
  3. Griffiths W, Judge M, Leigh I: Disorders of keratinization. (eds) Champion R, et al: Textbook of Dermatology Oxford, Blackwell Science, 1998;1486-1488
  4. Oji V, Tadini G, Akiyama M, et al: Revised nomenclature and classification of inherited ichthyoses: results of the first ichthyosis consensus conference in Sorèze 2009. J Am Acad Dermatol 2010;Epub, ahead of print
  5. Moskowitz DG, Fowler AJ, Heyman MB, et al: Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultra-structure, epidermal permeability barrier function, and energy expenditure. J Pediatr 2004;145:82-92
  6. Fowler AJ, Moskowitz DG, Wong A, Cohen SP, Williams ML, Heyman MB: Nutritional status and gastrointestinal structure and function in children with ichthyosis and growth failure. J Pediatr Gastroenterol Nutr 2004;38:164-169
  7. Allen A, Siegfried E, Silverman R, et al: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-750
  8. Smith DL, Smith JG, Wong SW, de Shazo RD: Netherton's syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol 1995;95:116-123
  9. Sprecher E, Chavanas S, Di Giovanna JJ, et al: The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001;117:179-187
  10. Richard G: Disorders of cornification. (eds) Sprecher E: Progress in Monogenic Hair Disorders New York, Nova Biomedical, 2006;153-196
  11. Saghari S, Woolery-Lloyd H, Nouri K: Squamous cell carcinoma in a patient with Netherton's syndrome. Int J Dermatol 2002;41:415-416
  12. Kubler HC, Kuhn W, Rummel HH, Kaufmann I, Kaufmann M: Development of cancer (vulvar cancer) in the Netherton syndrome (ichthyosis, hair anomalies, atopic diathesis (in German). Geburt-shilfe Frauenheilkd 1987;47:742-744
  13. Hintner H, Jaschke E, Fritsch P: Netherton syndrome: weakened immunity, generalized verrucosis and carcinogenesis (in German). Hautarzt 1980;31:428-432
  14. Krasagakis K, Ioannidou DJ, Stephanidou M, Manios A, Panayiotides JG, Tosca AD: Early development of multiple epithelial neoplasms in Netherton syndrome. Dermatology 2003;207:182-184
  15. Weber F, Fuchs PG, Pfister HJ, Hintner H, Fritsch P, Hoepfl R: Human papillomavirus infection in Netherton's syndrome. Br J Dermatol 2001;144:1044-1049
  16. Yamasaki K, Schauber J, Coda A, et al: Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. Faseb J 2006;20:2068-2080
  17. Ong PY, Ohtake T, Brandt C, et al: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-1160
  18. Wile U: Familial study of three unusual cases of congenital ichthyosiform erythroderma. Arch Dermatol Syphilol 1924;10:487-498
  19. Magert HJ, Standker L, Kreutzmann P, et al: LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999;274:21499-21502
  20. Chavanas S, Bodemer C, Rochat A, et al: Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25:141-142
  21. Bitoun E, Chavanas S, Irvine AD, et al: Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 2002;118:352-361
  22. Raghunath M, Tontsidou L, Oji V, et al: SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004;123:474-483
  23. Walden M, Kreutzmann P, Drögemüller K, John H, Forssmann WG, Mägert H-J: Biochemical features, molecular biology and clinical relevance of the human 15-domain serine proteinase inhibitor LEKTI. Biol Chem 2002;383:1139-1141
  24. Ishida-Yamamoto A, Deraison C, Bonnart C, et al: LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extra-cellular spaces of the superficial stratum granulosum. J Invest Dermatol 2005;124:360-366
  25. Hachem JP, Wagberg F, Schmuth M, et al: Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 2006;126:1609-1621
  26. Egelrud T, Brattsand M, Kreutzmann P, et al: hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br J Dermatol 2005;153:1200-1203
  27. Caubet C, Jonca N, Brattsand M, et al: Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/ KLK7/hK7. J Invest Dermatol 2004;122:1235-1244
  28. Borgono CA, Michael IP, Komatsu N, et al: A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 2007;282:3640-3652
  29. Schechter NM, Choi EJ, Wang ZM, et al: Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem 2005;386:1173-1184
  30. Descargues P, Deraison C, Prost C, et al: Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 2006;126:1622-1632
  31. Meyer-Hoffert U, Wu Z, Schroder JM: Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS One 2009;4:e4372
  32. Brattsand M, Stefansson K, Hubiche T, Nilsson SK, Egelrud T: SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor. J Invest Dermatol 2009;129:1656-1665
  33. Roelandt T, Thys B, Heughebaert C, et al: LEKTI-1 in sickness and in health. Int J Cosmet Sci 2009;31:247-254
  34. Briot A, Deraison C, Lacroix M, et al: Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 2009;206:1135-1147
  35. Descargues P, Deraison C, Bonnart C, et al: Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 2005;37:56-65
  36. Fartasch M, Williams ML, Elias PM: Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol 1999;135:823-832
  37. Thorne EG, Zelickson AS, Mottaz JH, Katz HI, Deaton BH: Netherton's syndrome: an electronmicroscopic study. Arch Dermatol Res 1975;253:177-183
  38. Mevorah B, Frenk E: Ichthyosis linearis circumflexa Comel with trichorrhexis invaginata (Netherton's syndrome): a light-microscopic study of the skin changes. Dermatologica 1974;149:193-200
  39. Zina AM, Bundino S: Ichthyosis linearis circumflexa Cornel and Netherton's syndrome: an ultra-structural study. Dermatologica 1979;158:404-412
  40. Frenk E, Mevorah B: Ichthyosis linearis circumflexa Comel with trichorrhexis invaginata (Netherton's syndrome): an ultrastructural study of the skin changes. Arch Dermatol Forsch 1972;245:42-49
  41. Hausser I, Anton-Lamprecht I, Hartschuh W, Petzoldt D: Netherton's syndrome: ultrastructure of the active lesion under retinoid therapy. Arch Dermatol Res 1989;281:165-172
  42. Nylander-Lundqvist E, Back O, Egelrud T: IL-1 beta activation in human epidermis. J Immunol 1996;157:1699-1704
  43. Elias PM: Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Exp Dermatol 1996;5:191-201
  44. Walley AJ, Chavanas S, Moffatt MF, et al: Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175-178
  45. Al-Ghamdi F, Al-Raddadi A, Satti M: Peeling skin syndrome: 11 cases from Saudi Arabia. Ann Saudi Med 2006;26:352-357
  46. Janjua SA, Hussain I, Khachemoune A: Facial peeling skin syndrome: a case report and a brief review. Int J Dermatol 2007;46:287-289
  47. Hashimoto K, Hamzavi I, Tanaka K, Shwayder T: Acral peeling skin syndrome. J Am Acad Dermatol 2000;43:1112-1119
  48. Cassidy AJ, van Steensel MA, Steijlen PM, et al: A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome. Am J Hum Genet 2005;77:909-917
  49. Kharfi M, El Fekih N, Ammar D, et al: A missense mutation in TGM5 causes acral peeling skin syndrome in a Tunisian family. J Invest Dermatol 2009;129:2512-2515
  50. Candi E, Oddi S, Terrinoni A, et al: Transglutaminase 5 cross-links loricrin, involucrin, and small prolinerich proteins in vitro. J Biol Chem 2001;276:35014-35023
  51. Geyer AS, Ratajczak P, Pol-Rodriguez M, Millar WS, Garzon M, Richard G: Netherton syndrome with extensive skin peeling and failure to thrive due to a homozygous frameshift mutation in SPINK5. Dermatology 2005;210:308-314
  52. Komatsu N, Suga Y, Saijoh K, et al: Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggest an over-desquamation of corneocytes. J Invest Dermatol 2006;126:2338-2342
  53. Oji V, Eckl K, Aufenvenne K, et al: Loss of corneodesmosin leads to severe skin barrier defect, pruritus and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010;in press
  54. Silverman AK, Ellis CN, Beals TF, Woo TY: Continual skin peeling syndrome: an electron microscopic study. Arch Dermatol 1986;122:71-75
  55. Brusasco A, Veraldi S, Tadini G, Caputo R: Localized peeling skin syndrome: case report with ultrastructural study. Br J Dermatol 1998;139:492-495
  56. Tsai K, Valente NY, Nico MM: Inflammatory peeling skin syndrome studied with electron microscopy. Pediatr Dermatol 2006;23:488-492

Article / Publication Details

Published online: September 14, 2010
Cover Date: 2010

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9394-6 (Print)
eISBN: 978-3-8055-9395-3 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP